Agenix![ext]()
(ASX: AGX) is advancing its product pipeline and adding to its human health diagnostics business with the execution of a licensing agreement with *Tyrian Diagnostics![ext]()
(ASX: TDX)*.
The deal will see Agenix![ext]()
licence exclusive worldwide royalty free rights to the human health application for Tyrian’s proprietary DiagnostIQ® rapid point-of-care test platform.
The molecular diagnostics market in the U.S. alone is around US$4 billion and is estimated to grow at a rate of 17% per annum.
Agenix![ext]()
will satisfy the acquisition by issuing $500,000 worth of shares in instalments by June 2014, which means it will not impact the company’s immediate cash requirements.
The shares to be issued to Tyrian currently represent less than 20% of the issued capital.
The DiagnostIQ® platform comprises a patented disposable test device which can be used for various applications, either alone or together with the DiagnostIQ® Reader for various human, animal and agricultural applications to determine action to be taken at the PoC (human and veterinary tests) or PoN (agricultural and environmental tests).
Agenix![ext]()
has licensed the rights to develop the DiagnostIQ® platform for human health applications and plans to develop the technology into a micro-array device to process multiple human health diagnostic tests on the one system.
The device is currently licensed to Bayer CropScience AG for an agricultural application.
DiagnostIQ® is covered by 15 patents registered in multiple jurisdictions to 2022 and has five patents pending.
In an addition to the licence, to be finalised in the near future, Agenix![ext]()
will also acquire a patent for Tyrian’s antibody-based test for active tuberculosis (TB).
This patent covers a novel biomarker, discovered by Tyrian, which has the potential to distinguish patients with active TB infection from those that have been infected in the past, or have been vaccinated.
*
Advanced diagnostics *
Agenix![ext]()
’s most advanced diagnostic candidate is ThromboView®, a novel radio-labelled monoclonal antibody imaging agent.
The company has completed two phase two clinical trials of the product that is ideal for the diagnosis of patients suspected of having acute pulmonary embolism.
ThromboView® has significant advantages compared with CT scans such as lower radiation dose, avoidance of exposure to allergenic or nephrotoxic contrast dye and ability to diagnose both pulmonary embolism and deep vein thrombosis with same scan.
The diagnostic is ready for phase three trials and is currently the subject of partnering and licensing discussions.
Agenix![ext]()
holds patents covering the technology in the U.S., Europe, Japan, Singapore, Australia and New Zealand with applications pending in China and Canada.
The company has successfully commercialised more than 20 products over four technology platforms since listing on the ASX in 1987.
*Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.* Reported by Proactive Investors 49 minutes ago.
(ASX: AGX) is advancing its product pipeline and adding to its human health diagnostics business with the execution of a licensing agreement with *Tyrian Diagnostics (ASX: TDX)*.The deal will see Agenix
licence exclusive worldwide royalty free rights to the human health application for Tyrian’s proprietary DiagnostIQ® rapid point-of-care test platform.The molecular diagnostics market in the U.S. alone is around US$4 billion and is estimated to grow at a rate of 17% per annum.
Agenix
will satisfy the acquisition by issuing $500,000 worth of shares in instalments by June 2014, which means it will not impact the company’s immediate cash requirements.The shares to be issued to Tyrian currently represent less than 20% of the issued capital.
The DiagnostIQ® platform comprises a patented disposable test device which can be used for various applications, either alone or together with the DiagnostIQ® Reader for various human, animal and agricultural applications to determine action to be taken at the PoC (human and veterinary tests) or PoN (agricultural and environmental tests).
Agenix
has licensed the rights to develop the DiagnostIQ® platform for human health applications and plans to develop the technology into a micro-array device to process multiple human health diagnostic tests on the one system.The device is currently licensed to Bayer CropScience AG for an agricultural application.
DiagnostIQ® is covered by 15 patents registered in multiple jurisdictions to 2022 and has five patents pending.
In an addition to the licence, to be finalised in the near future, Agenix
will also acquire a patent for Tyrian’s antibody-based test for active tuberculosis (TB).This patent covers a novel biomarker, discovered by Tyrian, which has the potential to distinguish patients with active TB infection from those that have been infected in the past, or have been vaccinated.
*
Advanced diagnostics *
Agenix
’s most advanced diagnostic candidate is ThromboView®, a novel radio-labelled monoclonal antibody imaging agent.The company has completed two phase two clinical trials of the product that is ideal for the diagnosis of patients suspected of having acute pulmonary embolism.
ThromboView® has significant advantages compared with CT scans such as lower radiation dose, avoidance of exposure to allergenic or nephrotoxic contrast dye and ability to diagnose both pulmonary embolism and deep vein thrombosis with same scan.
The diagnostic is ready for phase three trials and is currently the subject of partnering and licensing discussions.
Agenix
holds patents covering the technology in the U.S., Europe, Japan, Singapore, Australia and New Zealand with applications pending in China and Canada.The company has successfully commercialised more than 20 products over four technology platforms since listing on the ASX in 1987.
*Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.* Reported by Proactive Investors 49 minutes ago.